Compare CNC & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNC | GEHC |
|---|---|---|
| Founded | 1984 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0B | 29.1B |
| IPO Year | 2001 | 2022 |
| Metric | CNC | GEHC |
|---|---|---|
| Price | $68.05 | $76.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 22 |
| Target Price | $74.50 | ★ $86.80 |
| AVG Volume (30 Days) | ★ 3.9M | 3.6M |
| Earning Date | 10-27-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 0.21% |
| EPS Growth | N/A | ★ 4.84 |
| EPS | ★ 5.15 | 3.44 |
| Revenue | ★ $194,777,000,000.00 | $20,625,000,000.00 |
| Revenue This Year | $12.83 | $6.01 |
| Revenue Next Year | N/A | $4.75 |
| P/E Ratio | ★ $13.27 | $22.28 |
| Revenue Growth | ★ 19.44 | 4.84 |
| 52 Week Low | $31.63 | $58.75 |
| 52 Week High | $72.50 | $89.77 |
| Indicator | CNC | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 73.86 |
| Support Level | $63.36 | $68.88 |
| Resistance Level | $68.67 | $85.55 |
| Average True Range (ATR) | 2.70 | 1.82 |
| MACD | -0.21 | 0.85 |
| Stochastic Oscillator | 33.09 | 84.85 |
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).